Silence Therapeutics plc (NASDAQ:SLN) Receives $57.20 Consensus Target Price from Analysts

by · The Markets Daily

Silence Therapeutics plc (NASDAQ:SLN – Get Free Report) has been given a consensus rating of “Buy” by the six analysts that are currently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $57.20.

A number of equities research analysts recently weighed in on the company. BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. Morgan Stanley reaffirmed an “overweight” rating and issued a $49.00 price target on shares of Silence Therapeutics in a research note on Tuesday, October 8th. Chardan Capital restated a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a research report on Tuesday, December 10th. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Monday, December 9th.

Check Out Our Latest Report on SLN

Silence Therapeutics Price Performance

Silence Therapeutics stock opened at $5.99 on Wednesday. The company’s 50-day moving average is $9.07 and its 200-day moving average is $15.22. The firm has a market capitalization of $179.27 million, a PE ratio of -3.82 and a beta of 1.08. Silence Therapeutics has a fifty-two week low of $5.81 and a fifty-two week high of $27.72.

Institutional Investors Weigh In On Silence Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its position in Silence Therapeutics by 609.2% in the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after buying an additional 5,233 shares during the last quarter. Y Intercept Hong Kong Ltd lifted its position in shares of Silence Therapeutics by 22.9% during the third quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company’s stock worth $383,000 after acquiring an additional 3,923 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of Silence Therapeutics by 219.3% in the third quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock valued at $8,505,000 after acquiring an additional 321,300 shares during the period. Parkman Healthcare Partners LLC grew its position in Silence Therapeutics by 71.8% during the third quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock worth $9,051,000 after buying an additional 208,029 shares in the last quarter. Finally, Ikarian Capital LLC increased its position in shares of Silence Therapeutics by 15.9% in the third quarter. Ikarian Capital LLC now owns 587,343 shares of the company’s stock worth $10,678,000 after purchasing an additional 80,678 shares during the last quarter. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

(Get Free Report

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.

Featured Articles